Diverse perspectives on the current state of genomic medicine: has the revolution begun? by MacDermed, Dhara M & Uribe-Bruce, Liliana
Scripps Translational Science Institute (STSI, La Jolla, 
USA) hosted its 4th ‘Future of Genomic Medicine’ 
meeting, to promote the transformation of medicine 
using genomics. Th  e conference focused on recent 
advances in whole genome and exome sequencing, gene 
expression tests for routine medical practice, and 
consumer genomics. Clinically relevant genomic 
advances in cancer, diabetes and heart disease were 
discussed. ‘Views from the Outside’ sessions featured 
journalists, entrepreneurs and public ﬁ  gures presenting 
their perspectives on genomic medicine. Th  e speakers 
provided evidence that a revolution in genomic medicine 
is underway and involves not only medical doctors and 
scientists, but also those outside of the traditional 
scientiﬁ  c community. Here, we summarize some of the 
highlights of the medical advances and social implications 
discussed at this extraordinary meeting.
Advances in genomic medicine are already at 
the bedside
Genetic diagnostic tests, including whole genome 
sequencing, are already improving patient care. Gene 
expression proﬁ  ling in peripheral blood constitutes the 
basis for an FDA-approved, cost-eﬀ  ective  heart 
transplant rejection risk test. Matthew Price (Scripps 
Clinic, USA) described the use of the rapid point of care 
CYP2C19 genotyping test to identify patients with 
cardiac stents who will beneﬁ  t from clopidogrel, and the 
use of gene expression signatures such as CorusTM CAD 
(CardioDX®, Palo Alto, CA, USA) to detect coronary 
artery disease (CAD). Along the same lines, oncology 
experts described gene-proﬁ   ling-based diagnostic and 
prognostic tests such as MammaPrint® (Agendia, 
Amsterdam, Th   e Netherlands), Pathwork® Tissue of 
Origin (Pathwork Diagnostics, Redwood City, CA, USA), 
and Oncotype DX® (Genomic Health, Inc., Redwood City, 
CA, USA). Steven Shak (Genomic Health, Inc.), a 
developer of Oncotype DX®, pointed to a road map for 
developing similar tests by ﬁ  rst identifying a clear clinical 
dilemma, and then designing a multistep, multistudy 
approach to develop the assay. Howard Jacob (Children’s 
Hospital of Wisconsin, USA), presented the case of 
Nicholas Volker, a child with a devastating gastro-
intestinal disease that was a diagnostic mystery until his 
physician requested whole exome sequencing, which led 
to the identiﬁ   cation of an unsuspected gene variant 
associated with inﬂ   ammation and hematologic 
malignancies, pointing the way to a life-saving bone 
marrow transplant.
Tumor sequencing enables better understanding 
and treatment of cancer
Many cancer-related genes have been identiﬁ  ed in large-
scale sequencing projects. Some of these, such as B-RAF
and  K-RAS mutations, now provide individualized 
prognostic information. Recent data support the stance 
that personalized tumor biomarkers can be used to 
monitor tumor progression, and early genomic changes 
may be detectable even before cancer develops. Elaine 
Mardis (Washington University, USA), using next-
generation whole genome sequencing of tumors, has 
identiﬁ   ed similarities, yet many diﬀ  erences,  between 
primary tumors and metastases at diﬀ  erent  sites, 
suggesting separate clonal evolution. Similarly, Samuel 
Levy (STSI, USA) talked about the great value of exome 
sequencing and the importance of accounting for tumor 
heterogeneity; Levy presented preliminary data from a 
tumor mapping project in which biopsies were taken 
from multiple diﬀ  erent locations in a single tumor and 
nearby tissue, and sequences were determined. Daniel 
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© 2011 BioMed Central Ltdvon Hoﬀ    (T-Gen, USA) presented cases of patients 
treated successfully at his institution with targeted 
therapies that were selected based on individual tumor 
sequencing.
Improved risk prediction and management of 
diabetes and heart disease
Recent advances have been shown to be cost-eﬀ  ective 
and clinically useful in the treatment of diabetes and 
heart disease. After identifying 16 new loci contributing 
to the pathogenesis of type 1 diabetes (T1D), the T1D 
Genetic Consortium is transitioning from genome-wide 
association studies to gene discovery, and following 
strategies such as dense SNP mapping using the 
ImmunoChip, targeted sequencing studies in regions and 
exons of interest, and functional evaluation of genes 
associated with T1D. Advances in the pharmacogenomics 
of type 2 diabetes include the identiﬁ  cation of TCFL2 
variants as predictors of poor response to sulfonylurea 
treatment. Philippe Froguel (Imperial College, UK) 
discussed the cost-eﬀ   ectiveness of diagnostic whole 
genome sequencing and the improvements of quality of 
life for patients with monogenic forms of diabetes who 
can stop insulin treatment when correctly diagnosed by 
genomic testing. Stimulating advances in risk prediction 
have also been made in the ﬁ  eld of cardiology: by adding 
9p21 and another seven genetic risk factors to traditional 
CAD risk factor models, the deCODE MITM (deCODE 
Genetics, Iceland) test demonstrated increased sensitivity 
to predict myocardial infarction.
The public perception of medical genomics reveals 
promises and pitfalls
Th   e ‘Views from the Outside’ session provided a variety 
of perspectives on the impact of genomic medicine. 
Keynote speaker Juan Enriquez (Excel Venture 
Management, USA) believes that the genomic medicine 
biotechnology industry has the potential to foster 
economic growth, similar to the information technology 
industry. However, as an investor, he expressed concern 
about the elevating costs and overly stringent standards 
for drug development, as these may limit investor 
participation. In the ﬁ  eld of direct-to-consumer testing, 
Cinnamon Bloss (STSI, USA) presented the results of her 
study of behavioral consequences of direct-to-consumer 
genome-wide proﬁ  ling, where no additional anxiety was 
detected after learning genetic risk information for 
multiple diseases. Melanie Swan (DIYGenomics, USA) 
revealed a truly revolutionary enterprise where 
consumers, armed with their own genotyping 
information from commercial platforms, design and 
conduct their research studies using her web-based 
DIYGenomics organization. Th  is probably reﬂ  ects what 
Eric Topol (Director, STSI, USA) referred to as the 
‘democratization of American medicine’, as the explosion 
in technologies and social networking result in a 
transformation in healthcare and medical research. Amy 
Harmon (Th  e New York Times, USA) presented a 
cautionary tale about a clinical trial of an agent targeting 
B-RAF mutated melanoma. Despite unprecedented 
success and evidence of response to this new targeted 
agent in nearly all patients in initial studies, a randomized 
clinical trial was initiated, in which half the patients were 
assigned to the recognized standard treatment, known to 
have poor eﬃ   cacy, and were not given the opportunity to 
try the new treatment option. Harmon made a case for 
the need for more open conversations about research and 
its ethical implications with the public and with patients. 
She encouraged the use of open-access publications.
The bright future of genomic medicine
Th  e current price of sequencing a whole single genome 
was estimated to be approximately US$30,000, but this 
ﬁ  gure appears to be dropping rapidly. Several speakers 
predicted that the cost of analyzing the ever-expanding 
amount of genomic data and presenting it in a meaningful 
format to physicians and patients is likely to become 
greater than the cost of sequencing itself. Clearly, 
genomic medicine is already beneﬁ   ting many patients 
and our evolving tools are rapidly expanding its reach. 
Clinical applications in cancer, diabetes, heart disease 
and other conditions are improving patient care and our 
ongoing discoveries should facilitate further translational 
advances. At the same time, investigators need to be 
attentive to the needs of patients and communities, and 
improve communication with physicians and other 
individuals outside of our ﬁ  eld as we move forward.
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